BMS-813160 Uses, Dosage, Side Effects and more
BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).
| Trade Name | BMS-813160 |
| Generic | BMS-813160 |
| Type | |
| Formula | C25H40N8O2 |
| Weight | Average: 484.649 Monoisotopic: 484.32742256 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
